| Literature DB >> 17324118 |
Carmen Dumaual1, Xin Miao, Thomas M Daly, Carsten Bruckner, Reuben Njau, Dong-Jing Fu, Sandra Close-Kirkwood, Nancy Bauer, Nancy Watanabe, Paul Hardenbol, Richard D Hockett.
Abstract
The combined effects of multiple polymorphisms in several drug-metabolizing enzyme and transporter genes can contribute to considerable interindividual variation in drug disposition and response. Therefore, it has been of increasing interest to generate scalable, flexible and cost-effective technologies for large-scale genotyping of the drug-metabolizing enzyme and transporter genes. However, the number of drug-metabolizing enzyme and transporter gene variants exceeds the capacity of current technologies to comprehensively assess multiple polymorphisms in a single, multiplexed assay. The Targeted Genotyping System (Affymetrix, CA, USA) provides a solution to this challenge, by combining molecular inversion probe technology with universal microarrays to provide a method that is capable of analyzing thousands of variants in a single reaction, while remaining relatively insensitive to cross-reactivity between reaction components. This review will focus on the Targeted Genotyping System and how this technology was adapted to enable comprehensive analysis of drug-metabolizing enzyme and transporter gene polymorphisms.Mesh:
Substances:
Year: 2007 PMID: 17324118 DOI: 10.2217/14622416.8.3.293
Source DB: PubMed Journal: Pharmacogenomics ISSN: 1462-2416 Impact factor: 2.533